JP2017530372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530372A5 JP2017530372A5 JP2017533704A JP2017533704A JP2017530372A5 JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5 JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pharmaceutical composition
- patient
- domain
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US62/051,091 | 2014-09-16 | ||
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| US62/099,630 | 2015-01-05 | ||
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530372A JP2017530372A (ja) | 2017-10-12 |
| JP2017530372A5 true JP2017530372A5 (enExample) | 2018-10-11 |
| JP6692358B2 JP6692358B2 (ja) | 2020-05-13 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533704A Active JP6692358B2 (ja) | 2014-09-16 | 2015-09-10 | 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (enExample) |
| EP (1) | EP3194974B1 (enExample) |
| JP (1) | JP6692358B2 (enExample) |
| KR (1) | KR102471057B1 (enExample) |
| CN (1) | CN107076749B (enExample) |
| AU (1) | AU2015318207B2 (enExample) |
| CA (1) | CA2960890A1 (enExample) |
| EA (1) | EA036671B1 (enExample) |
| IL (1) | IL250905B (enExample) |
| MX (1) | MX382673B (enExample) |
| WO (1) | WO2016044041A1 (enExample) |
| ZA (1) | ZA201701664B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971054A4 (en) | 2013-03-14 | 2017-04-12 | Otraces Inc. | A method for improving disease diagnosis using measured analytes |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3011988A1 (en) | 2016-01-22 | 2017-07-27 | Otraces Inc. | Systems and methods for improving disease diagnosis |
| WO2018181881A1 (ja) * | 2017-03-31 | 2018-10-04 | 株式会社Ｈｉｒｏｔｓｕバイオサイエンス | がん患者の治療効果の予測および／または再発モニタリング |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| US20210012899A1 (en) * | 2019-07-13 | 2021-01-14 | Otraces, Inc. | Diagnosis for various diseases using tumor microenvironment active proteins |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US12656349B2 (en) | 2019-10-17 | 2026-06-16 | Board Of Regents, The University Of Texas System | Measurement of bevacizumab-insensitive vascular endothelial growth factor-a |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| AU2010282274A1 (en) * | 2009-08-14 | 2012-03-15 | Allergan, Inc. | Methods of treating cancer using growth factor retargeted endopeptidases |
| WO2011089101A1 (en) | 2010-01-19 | 2011-07-28 | F. Hoffmann-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| CN104634971A (zh) | 2010-07-19 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies | |
| Linger et al. | Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors | |
| Lurje et al. | EGFR signaling and drug discovery | |
| Chuma et al. | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions | |
| Zarrin et al. | Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance | |
| JP2016539096A5 (enExample) | ||
| JP2015525230A5 (enExample) | ||
| Luo et al. | Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors | |
| JP2016527221A5 (enExample) | ||
| KR20140148412A (ko) | 단일특이적 및 이중특이적인 항-igf-1r 및 항-erbb3 항체의 용량 및 투여 | |
| JP2015506961A5 (enExample) | ||
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| MX2018008849A (es) | Diagnostico diferencial de sindrome de cushing ectopico. | |
| CN107076749A (zh) | 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 | |
| Yu et al. | Targeted therapy for advanced or metastatic cholangiocarcinoma: focus on the clinical potential of infigratinib | |
| Ward et al. | Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis | |
| JP2016520583A5 (enExample) | ||
| Pirker et al. | Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine? | |
| Zhang et al. | Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy | |
| JP2016514130A5 (enExample) | ||
| RU2015154985A (ru) | Способы лечения рака | |
| Zheng et al. | Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC | |
| Davidsen et al. | The role of Axl receptor tyrosine kinase in tumor cell plasticity and therapy resistance | |
| JP2017535548A5 (enExample) | ||
| Zhao et al. | Overview of fundamental study of pazopanib in cancer |